Biotech | March 11, 2022
Moderna begins Phase 2 study of Omicron-specific bivalent booster
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
It will be the first and only global office for traditional medicine in the world
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Subscribe To Our Newsletter & Stay Updated
